Overview

A Phase 1 Study to Assess HM15275 in Healthy and Obese Subjects.

Status:
COMPLETED
Trial end date:
2025-05-02
Target enrollment:
Participant gender:
Summary
This Study is a Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15275 in Healthy and Obese Subjects.
Phase:
PHASE1
Details
Lead Sponsor:
Hanmi Pharmaceutical Company Limited